A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

Key developments in the health sector include Abbott's profit boost from medical sales, the UK's assisted dying law debate, Donald Trump's reproductive remarks, BAT's synthetic nicotine launch, ...

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...

The Boston Globe reports on findings from researchers at Mass General Brigham who examined "reservoirs" of the covid virus that hide inside people after their acute infections have ended. Also in the ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in ...

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...